As nicotine products evolve, public health policies must adapt to reflect scientific evidence and advance harm reduction goals. Central to this evolution is the idea of risk-proportionate taxation—a fiscal framework that aligns tax rates with the relative health risks of different nicotine products. This approach not only supports harm reduction but also incentivizes smokers to…
As the U.K. Parliament advances the Tobacco and Vapes Bill, a key feature is the introduction of a licensing scheme for retailers of nicotine pouches and alternative nicotine products. This initiative aims to regulate sales and storage, ensuring public health and safety. What Retailers Need to Know 🔹 Dual Licensing Requirement: Retailers must obtain both…
As the UK Tobacco and Vapes Bill advances in the House of Commons, GINN is preparing to contribute its insights. We believe the regulatory framework must balance innovation with public health while ensuring consumer safety. Here’s what we propose: 🔹 Market Access: Introduce a clear and transparent notification process for manufacturers, requiring detailed disclosures of…
As the European Union considers new tax measures under the proposed revision of the Tobacco Excise Directive (TED), the focus on nicotine pouches highlights the growing debate over their regulation and taxation. This burgeoning segment within the nicotine market holds promise for harm reduction, but significant taxation could undermine its potential to encourage smokers to…
Nicotine and tobacco products exist on a spectrum of risk, ranging from the highest to the lowest health impact. This risk continuum provides a valuable framework for understanding the varying health effects of these products on individuals and populations, empowering people to make more informed decisions for their health. The High-Risk End: Combustible Tobacco Products…
Greece has emerged as a leader in innovative strategies to reduce smoking-related harm, reflecting its commitment to improving public health. Over the past few years, the country has introduced comprehensive measures to combat smoking while embracing harm reduction as a pivotal part of its national strategy. The National Action Plan Against Smoking In November 2019,…
Nicotine, widely known for its association with tobacco products, is also recognized as an approved drug by health authorities such as the World Health Organization (WHO). In therapeutic contexts, nicotine plays a pivotal role in smoking cessation strategies, offering safer alternatives to combustible tobacco use. When delivered without the harmful effects of combustion, nicotine replacement…
At the inaugural session of GINN’s in-person panels, hosted by the Global Institute for Novel Nicotine (GINN), key industry leaders gathered to address the evolving landscape of the nicotine pouch industry. This landmark event was not only a platform for sharing insights but also for delineating the path forward amid changing regulatory environments and market…
The 2024 Global Anti-Smoking Index, as presented by “We Are Innovation” highlights significant advancements in tobacco control and harm reduction strategies across diverse regions. While certain nations shine as leaders in this space, others lag behind, underscoring the urgent need for equitable and effective global tobacco policies. European Nations Dominate the Top 20 European countries…
Recently, I came across an update on Sweden’s progress that included fascinating insights from Professor Fredrik Nystrom.His perspectives were nothing short of captivating, particularly his insights on the metabolic interplay between nicotine and coffee. Inspired by his talk, I have begun reading his book, which challenges many conventional health norms with a refreshing scientific rigor.…